Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

BridgeBio Soars 52% And Breaks Out After Smashing Expectations In A Dwarfism Study

BridgeBio Pharma smashed Wall Street's expectations in a study of children with dwarfism, leading BBIO stock to break out in massive volume.

Investors Business Daily

Cramlington's Merit enlisted for £150m Moderna vaccine hub scheme

Hundreds of construction jobs will be created through the Moderna Innovation and Technology Centre (MITC) project

Birmingham Post

Trudeau says cocaine licenses are not for selling drug to public

Ottawa (AFP) - Prime Minister Justin Trudeau said Friday he was "surprised" that companies licensed to sell cocaine to pharmacists or hospitals seemed to signal Canada would soon allow legal sales of hard drugs to the public.

AFP

From analysis to the latest developments in health,
read the most diverse news in one place.

Reporter behind viral Eli Lilly parody account peels back curtain on ‘stupid little tweet’ that helped trigger insulin price cap

Reporter Sean Morrow wants to make sure credit goes to lawmakers working on drug pricing, Graig Graziosi reports

The Independent UK

The implications of Walgreens' decision on abortion pills

Walgreens says it will not start selling an abortion pill in 20 states that had warned of legal consequences if it did that

The Independent UK

Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating

Kala Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 67 to 83.

Investors Business Daily

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks With Potential to Be Big Winners in 2023

The biotech industry is well-positioned to grow strongly, given the ever-rising demand for therapies and favorable government initiatives. Looking at the industry’s long-term prospects, fundamentally strong biotech stocks Amgen (AMGN), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) could emerge as big winners this year. Keep reading….

StockNews.com

AstraZeneca's Trading Range Makes This Options Trade Appealing

AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are…

Investors Business Daily

3 Best Stocks to Own for Passive Income in 2023

The Fed is expected to keep hiking rates to achieve its target inflation rate. Amid rising volatility, investor sentiment toward dividend investing has been improving. Here are three quality dividend-paying stocks, Novartis (NVS), Bristol-Myers Squibb (BMY), and Canon (CAJ), which will ensure a steady passive income stream in 2023. Keep…

StockNews.com

FDA has new leverage over companies looking for a quicker drug approval

The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.

WEKU

‘Hero’ journalist congratulated after Eli Lilly lowers price of insulin after his spoof tweet raised awareness

Eli Lilly’s CEO challenged other pharmaceutical companies to drop insulin prices as well

The Independent UK

Victoria tips $10m into mRNA vaccine workforce training

Victoria is pouring $10 million into training Australia's vaccine workforce, ahead of the southern hemisphere's first mRNA production site opening in 2024.

The New Daily

Rarecan eyes up to £3m investment this year as cancer platform targets rapidly growing market

The Hexham-based start-up is on the hunt for a lead investor to take it into its next funding round

Birmingham Post

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy

Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed.

AFP

Vaccine maker Novavax says 'substantial doubt' over future

Washington (AFP) - Covid-19 vaccine maker Novavax raised doubts Tuesday about its ability to continue its business, announcing plans to cut spending after struggles in rolling out its coronavirus jab.

Tribune News Service

Pfizer’s RSV vaccine wins US panel’s backing for safety in older people

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

Investors Business Daily

uniQure Stock Trying To Close In On Key Technical Measure

A Relative Strength Rating upgrade for uniQure shows improving technical performance. Will it continue?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novavax Stock Plummets On 'Substantial Uncertainty' For Its Future

Novavax says there's "substantial doubt" regarding its ability to continue, and NVAX stock crashed Wednesday.

Birmingham Post

Croda's sales top £2b as profits hit £500m for East Yorkshire smart science giant

Powerful operating model and consistent execution hailed as record performance revealed

Tribune News Service

After capping insulin copays, Colorado sets its sights on EpiPens

Almost four years after becoming the first state to cap insulin copayments, Colorado may limit what consumers pay for epinephrine autoinjectors, also known as EpiPens, which treat serious allergic reactions.

Investors Business Daily

'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover

Pfizer is in early talks to acquire cancer specialist Seagen, according to a report that sent SGEN stock flying on Monday.

StockNews.com

1 Dividend Stock to Buy for Passive Income in 2023

Healthcare giant Johnson & Johnson (JNJ) has a six-decade-long history of consecutive dividend growth. So, given the uncertainties surrounding the market, this fundamentally strong dividend-paying stock might be an ideal buy now. Read more.

Insider UK

Glasgow university spin-out secures £8.75 million for tennis elbow treatment trials

The business will use the new funds to advance development of its microRNA therapeutics

ABC News

Queensland government announces pill testing trial at fixed and mobile sites

The government announces it is developing protocols around how the testing will operate, and is searching for a provider to trial at fixed and mobile locations in the state.

1 … 43 44 45 46

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.